ENAH and osteosarcoma: Metastatic samples had either 1.8 greater SRGAP2C: SRGAP2 transcript ratio (n = 2) (Fig. 4a) or a two-fold reduction of ENAH compared to primary osteosarcoma samples (n = 5) (Fig. 4b).